Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study

Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study

Abstract EGFR inhibitors have revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). Mefatinib is a novel, bioavailable, second-generation, irreversible pan-EGFR inhibitor. This phase Ib/II open-label, single-arm, multi-center study investigated the efficacy, safety, biomarker,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Pingli Wang, Yuping Li, Dongqing Lv, Lingge Yang, Liren Ding, Jianya Zhou, Wei Hong, Youfei Chen, Dongqing Zhang, Susu He, Jianying Zhou, Kai Wang
Formato: article
Lenguaje:EN
Publicado: Nature Publishing Group 2021
Materias:
Medicine
R
Biology (General)
QH301-705.5
Acceso en línea:https://doaj.org/article/3462325a99c64cee9618bf7e0eed72e4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/3462325a99c64cee9618bf7e0eed72e4

Ejemplares similares